CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 3, 2006--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - News) today announced that several preclinical studies being presented at the American Association for Cancer Research (AACR) annual meeting demonstrate broad anti-cancer activity of ARIAD’s oncogenic kinase inhibitors and bone-targeted mTOR inhibitors - new molecularly targeted oncology therapies.
